Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome (2022)
- Authors:
- USP affiliated authors: SILVA, CLOVIS ARTUR ALMEIDA DA - FM ; KUPA, LEONARD DE VINCI KANDA - FM ; BORBA NETO, EDUARDO FERREIRA - FM ; BONFA, ELOISA SILVA DUTRA DE OLIVEIRA - FM
- Unidade: FM
- DOI: 10.1177/09612033221102073
- Subjects: COVID-19; ANTICORPOS ANTIFOSFOLIPÍDEOS; IMUNOGENÉTICA; FATORES DE RISCO; COAGULAÇÃO SANGUÍNEA
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: green
-
ABNT
SIGNORELLI, Flavio et al. Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome. Lupus, v. 31, n. 8, p. 974-984, 2022Tradução . . Disponível em: https://doi.org/10.1177/09612033221102073. Acesso em: 27 dez. 2025. -
APA
Signorelli, F., Balbi, G. G. M., Aikawa, N. E., Silva, C. A. A. da, Kupa, L. de V. K., Medeiros-Ribeiro, A. C., et al. (2022). Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome. Lupus, 31( 8), 974-984. doi:10.1177/09612033221102073 -
NLM
Signorelli F, Balbi GGM, Aikawa NE, Silva CAA da, Kupa L de VK, Medeiros-Ribeiro AC, Yuki EFN, Pasoto SG, Saad CGS, Borba Neto EF, Bonfa ESD de O. Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome [Internet]. Lupus. 2022 ; 31( 8): 974-984.[citado 2025 dez. 27 ] Available from: https://doi.org/10.1177/09612033221102073 -
Vancouver
Signorelli F, Balbi GGM, Aikawa NE, Silva CAA da, Kupa L de VK, Medeiros-Ribeiro AC, Yuki EFN, Pasoto SG, Saad CGS, Borba Neto EF, Bonfa ESD de O. Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome [Internet]. Lupus. 2022 ; 31( 8): 974-984.[citado 2025 dez. 27 ] Available from: https://doi.org/10.1177/09612033221102073 - Impact of distinct therapies on antibody response to SARS-CoV-2 vaccine in systemic lupus erythematosus
- Short-term Accrual 2019 European League Against Rheumatism/American College of Rheumatology Domains and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage in Lupus Patients With and Without Nephritis at Disease Onset
- First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR)
- 2019-EULAR/ACR classification criteria domains at diagnosis: predictive factors of long-term damage in systemic lupus erythematosus
- Thalidomide measurement in plasma and dried plasma spot by SPE combined with UHPLC-MS/MS for therapeutic drug monitoring
- SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy
- Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2
- Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis
- Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial
- Lúpus eritematoso sistêmico
Informações sobre o DOI: 10.1177/09612033221102073 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
